Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/33039

Title:	Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Authors:	Swain, S M Schneeweiss, A Gianni, L Gao, J J Stein, A Waldron-Lynch, M Heeson, S Beattie, Sara M Yoo, B Cortes, J Baselga, J View more
Keywords:	EGFR HER2 breast cancer diarrhea docetaxel pertuzumab View more
Mesh:	Adult Aged Antibodies, Monoclonal, Humanized Antineoplastic Agents Breast Neoplasms Chemotherapy-Induced Febrile Neutropenia Diarrhea Female Humans Incidence Middle Aged Receptor, ErbB-2 View more
Issue Date:	2017
Citation:	Ann. Oncol..2017 04;(28)4:761-768
Abstract:	Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the incidence and severity of diarrhea observed with pertuzumab in the CLEOPATRA, NeoSphere, and TRYPHAENA studies.
PMID:	28057664
URI:	https://hdl.handle.net/20.500.12530/33039
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC5834072.pdf		284.58 kB	Adobe PDF	View/Open